Green Cross Of S. Korea Said Freed To Take Orders For H1N1 Flu Vaccine
This article was originally published in PharmAsia News
South Korea's Green Cross said its H1N1 influenza vaccine GCFlu has been approved for marketing by the Korea FDA, ending the nation's reliance on imports and freeing the company to take orders for its drug. Green Cross said it would have produced by the end of July enough doses for 3.3 million, rising to 5 million people covered by the end of the year. South Korea thus becomes the world's 12 vaccine producer. (Click here for more
You may also be interested in...
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.
The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.